Neurogene (NASDAQ:NGNE) Receives “Buy” Rating from HC Wainwright

Neurogene (NASDAQ:NGNE)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $55.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 170.94% from the stock’s current price.

A number of other analysts have also recently commented on NGNE. Robert W. Baird upped their price target on shares of Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Leerink Partners upped their price target on shares of Neurogene from $45.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Stifel Nicolaus upped their price target on shares of Neurogene from $44.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. BMO Capital Markets cut their price target on shares of Neurogene from $60.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. Finally, William Blair reissued an “outperform” rating on shares of Neurogene in a research report on Tuesday, November 19th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $60.83.

Neurogene Stock Up 30.2 %

Shares of NGNE opened at $20.30 on Monday. The firm’s fifty day simple moving average is $44.97 and its two-hundred day simple moving average is $39.62. Neurogene has a 12 month low of $12.49 and a 12 month high of $74.49.

Institutional Investors Weigh In On Neurogene

Institutional investors and hedge funds have recently made changes to their positions in the business. RTW Investments LP increased its stake in Neurogene by 6.0% in the 3rd quarter. RTW Investments LP now owns 1,135,256 shares of the company’s stock valued at $47,635,000 after buying an additional 64,691 shares during the last quarter. FMR LLC increased its stake in Neurogene by 912.4% in the 3rd quarter. FMR LLC now owns 731,801 shares of the company’s stock valued at $30,706,000 after buying an additional 659,515 shares during the last quarter. Vanguard Group Inc. increased its stake in Neurogene by 906.5% in the 1st quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after buying an additional 457,062 shares during the last quarter. State Street Corp increased its stake in Neurogene by 17.5% in the 3rd quarter. State Street Corp now owns 246,540 shares of the company’s stock valued at $10,345,000 after buying an additional 36,687 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its stake in Neurogene by 123.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after buying an additional 56,533 shares during the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.